Intravenous methylprednisolone for thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests two different ways of giving a steroid medicine called methylprednisolone through an IV to treat thyroid eye disease (also called Graves orbitopathy), which causes bulging and inflammation of the eyes. The goal is to see which schedule works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have moderate-to-severe thyroid eye disease with active inflammation (score of 3 or higher on a specific scale)
- Your thyroid hormone levels have been normal for at least 2 months, either with medicine, surgery, or at least 6 months after radioactive iodine treatment
- You have not had any prior treatment that suppresses the immune system for your eye disease
- You have not had any steroids or immune-suppressing drugs for any reason in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether high-dose steroid pulses (given through a vein) can help people with moderate to severe Graves' eye disease that is still active. It is for people who have not yet been treated with steroids and whose eye problems began within the past year.
This trial tests whether atorvastatin, a common cholesterol medicine, can reduce inflammation and improve eye symptoms in people with moderate-to-severe thyroid eye disease. It may help by calming the immune response that causes the eye problems.
This trial compares a newer medication (teprotumumab) with standard steroid treatment for people with thyroid eye disease and vision loss who are about to have urgent surgery to relieve pressure on the optic nerve. The goal is to see which approach better protects and restores vision after surgery.
This trial studies whether hydroxychloroquine can improve mild Graves’ orbitopathy (swelling and discomfort around the eyes). It’s meant for people with mild symptoms and who haven’t recently used certain eye or immune treatments.
This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Hear when a new Graves Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.